Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Mindset Pharma Inc. (MSSTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4959-0.0781 (-13.61%)
At close: 03:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5740
Open0.5571
BidN/A x N/A
AskN/A x N/A
Day's Range0.4959 - 0.5632
52 Week Range0.2959 - 1.0718
Volume42,115
Avg. Volume46,270
Market Cap43.59M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1760
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    The Power Play by The Market Herald Interviews James Lanthier of Mindset Pharma

    VANCOUVER, BC / ACCESSWIRE / January 5, 2022 / The Power Play by The Market Herald has announced the release of a new interview with Mindset Pharma on their latest news.The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.

  • CNW Group

    IIROC Trade Resumption - MSET

    Trading resumes in:

  • GlobeNewswire

    The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines

    PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, and Mindset Pharma Inc. (Mindset) (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) today announce a collaboration that will support the development of psychedelic medicines. MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, a drug discovery and develo

Advertisement
Advertisement